US2015094378A1PendingUtilityA1

Inhalable Epinephrine

60
Assignee: CIVITAS THERAPEUTICS INCPriority: Jun 28, 2002Filed: May 1, 2014Published: Apr 2, 2015
Est. expiryJun 28, 2022(expired)· nominal 20-yr term from priority
A61P 37/08A61P 25/00A61K 31/137A61K 31/135A61M 2202/06A61K 9/0075A61K 9/1617A61M 15/0091A61K 9/0073
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.

Claims

exact text as granted — not AI-modified
1 . Spray-dried particles for the delivery of epinephrine to the respiratory system of a patient, the particles comprising:
 (a) epinephrine or a salt thereof; and   (b) at least one pharmaceutically acceptable excipient wherein at least one excipient is crystalline or amorphous.   
     
     
         2 . The particles of  claim 1 , wherein the epinephrine or salt thereof, is present in the particles in an amount ranging from about 1 to about 95 weight percent. 
     
     
         3 . The particles of  claim 2 , wherein the epinephrine or salt thereof, is present in the particles in an amount ranging from about 1 to about 45 weight percent. 
     
     
         4 . The particles of  claim 3 , wherein the epinephrine or salt thereof, is present in the particles in an amount ranging from about 1 to about 30 weight percent. 
     
     
         5 . The particles of  claim 1 , wherein the particles are aerodynamically light. 
     
     
         6 . The particles of  claim 1 , wherein the particles comprise at least 50 micrograms of epinephrine. 
     
     
         7 . The particles of  claim 1 , wherein the particles are amorphous. 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . The particles of  claim 1 , wherein the particles are delivered to the respiratory system via inhalation. 
     
     
         11 . The particles of  claim 10 , wherein the particles comprise at least about 50 micrograms of epinephrine and are administered in a single inhalation. 
     
     
         12 . The particles of  claim 11 , wherein the particles comprise about 250 micrograms to about 5 milligrams of epinephrine and are administered in a single inhalation. 
     
     
         13 . The particles of  claim 1 , wherein the particles are administered to the respiratory system via a breath activated inhaler. 
     
     
         14 . The particles of  claim 13 , wherein the particles are administered to the respiratory system in a single breath activated step. 
     
     
         15 . The particles of  claim 1 , wherein the epinephrine is released from the particles and acts systemically. 
     
     
         16 . The particles of  claim 1  comprising:
 (a) epinephrine or a salt thereof; 
 (b) at least one pharmaceutically acceptable excipient wherein at least one excipient is crystalline or amorphous; and 
 (c) leucine in an amount of from about 62 to about 82 weight percent.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.